Janux Therapeutics, Inc.

JANXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1817713

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$54.9M	$53.4M	$53.4M	$26.2M	$3.0M
Operating Income (Loss)	-$73.0M	-$67.1M	-$67.1M	-$32.9M	-$4.8M
Nonoperating Income (Expense)	$14.7M	$4.0M	$4.0M	$257.0K	-$1.9M
Income Tax Expense (Benefit)	$0.00	—	—	—	—
Net Income (Loss) Attributable to Parent	-$58.3M	-$63.1M	-$63.1M	-$32.7M	-$6.8M
Earnings Per Share, Basic	-$1.32	-$1.52	-$1.52	-$1.39	—
Earnings Per Share, Diluted	-$1.32	-$1.52	-$1.52	-$1.39	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$1.1B	$380.4M	$364.0M	$379.8M	$16.2M
Assets, Current	$1.0B	$349.2M	$332.4M	$377.0M	$16.1M
Cash and Cash Equivalents, at Carrying Value	$430.6M	$19.2M	$51.4M	$35.6M	$7.8M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	$0.00	$0.00	$8.0M
Liabilities	$38.7M	$36.1M	$43.3M	$13.5M	$9.2M
Liabilities, Current	$17.5M	$13.0M	$16.5M	$12.8M	$3.2M
Accounts Payable, Current	$4.0M	$2.4M	$2.2M	$2.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$50.6M	-$42.9M	-$42.9M	-$17.0M	-$4.4M
Net Cash Provided by (Used in) Investing Activities	-$41.2M	$58.3M	$58.3M	-$341.0M	$0.00
Net Cash Provided by (Used in) Financing Activities	$59.5M	$500.0K	$500.0K	$386.5M	$11.5M
Payments to Acquire Property, Plant, and Equipment	$1.9M	$6.4M	$6.4M	$1.5M	$0.00

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)